TrialDiabetes, obesity & metabolism2022

Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD-11 study.

David A Cox et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.